1473 related articles for article (PubMed ID: 26719230)
1. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
Scagliotti GV; Gaafar R; Nowak AK; Nakano T; van Meerbeeck J; Popat S; Vogelzang NJ; Grosso F; Aboelhassan R; Jakopovic M; Ceresoli GL; Taylor P; Orlandi F; Fennell DA; Novello S; Scherpereel A; Kuribayashi K; Cedres S; Sørensen JB; Pavlakis N; Reck M; Velema D; von Wangenheim U; Kim M; Barrueco J; Tsao AS
Lancet Respir Med; 2019 Jul; 7(7):569-580. PubMed ID: 31103412
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
4. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
6. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
7. Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
Eberst G; Anota A; Scherpereel A; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Léna H; Rivière F; Monnet I; Gounant V; Janicot H; Gervais R; Locher C; Charton E; Morin F; Zalcman G; Westeel V;
Clin Cancer Res; 2019 Oct; 25(19):5759-5765. PubMed ID: 31175096
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
Grosso F; Steele N; Novello S; Nowak AK; Popat S; Greillier L; John T; Leighl NB; Reck M; Taylor P; Planchard D; Sørensen JB; Socinski MA; von Wangenheim U; Loembé AB; Barrueco J; Morsli N; Scagliotti G
J Clin Oncol; 2017 Nov; 35(31):3591-3600. PubMed ID: 28892431
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
12. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
Dowell JE; Dunphy FR; Taub RN; Gerber DE; Ngov L; Yan J; Xie Y; Kindler HL
Lung Cancer; 2012 Sep; 77(3):567-71. PubMed ID: 22770372
[TBL] [Abstract][Full Text] [Related]
13. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.
Nakano T; Kuribayashi K; Kondo M; Morise M; Tada Y; Hirano K; Hayashi M; Tanaka M; Hirabayashi M
Asia Pac J Clin Oncol; 2021 Jun; 17(3):264-272. PubMed ID: 32893992
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial.
Zhan M; Zheng H; Xu T; Yang Y; Li Q
Lung Cancer; 2017 Aug; 110():1-6. PubMed ID: 28676211
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Chu Q; Perrone F; Greillier L; Tu W; Piccirillo MC; Grosso F; Lo Russo G; Florescu M; Mencoboni M; Morabito A; Cecere FL; Ceresoli GL; Dawe DE; Zucali PA; Pagano M; Goffin JR; Sanchez ML; Gridelli C; Zalcman G; Quantin X; Westeel V; Gargiulo P; Delfanti S; Tu D; Lee CW; Leighl N; Sederias J; Brown-Walker P; Luo Y; Lantuejoul S; Tsao MS; Scherpereel A; Bradbury P; Laurie SA; Seymour L
Lancet; 2023 Dec; 402(10419):2295-2306. PubMed ID: 37931632
[TBL] [Abstract][Full Text] [Related]
19. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
[TBL] [Abstract][Full Text] [Related]
20. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]